Home About Us Pipeline News Investors Contacts Careers


News

Recent Press Releases Archives

Recent Press Releases

2019 News Releases

May 9, 2019 - Puma Biotechnology Reports First Quarter 2019 Financial Results
Read

May 8, 2019 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019
Read

April 25, 2019 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

April 9, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

April 4, 2019 - Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations
Read

April 1, 2019 - Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe
Read

March 28, 2019 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019
Read

March 18, 2019 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting - Oral Plenary Presentation Receives SGO Presidential Award
Read

March 18, 2019 - Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

March 5, 2019 - Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
Read

February 28, 2019 - Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results
Read

February 15, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

February 13, 2019 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Read

February 4, 2019 - Puma Biotechnology Announces Litigation Victory with Jury’s Decision
Read

January 11, 2019 - Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada
Read

January 3, 2019 - Puma Biotechnology to Present at J. P. Morgan Healthcare Conference
Read

January 2, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read




Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax